ReviewCurrent HIV/AIDS reports2015
The role of statins in the setting of HIV infection.
Review in Current HIV/AIDS reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study.AIDS research and therapy · 2023Trial
- Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial.F1000Research · 2021Trial
- Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Trial
- HIV, Inflammation, and Immunometabolism: A Model of the Inflammatory Theory of Disease.Viruses · 2025Review
- Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025Review
- Article
- Statin use for cardiovascular disease prevention: perceptions among people living with HIV in the United States.BMC primary care · 2024Article
- Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.Frontiers in immunology · 2024Review
- Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection.Molecular and cellular biochemistry · 2023Review
- Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome-An Extempore Game of Misfiring with Defense Arsenals.Pathogens (Basel, Switzerland) · 2023Review
- Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation.Journal of acquired immune deficiency syndromes (1999) · 2022Article
- Atherosclerosis in HIV Patients: What Do We Know so Far?International journal of molecular sciences · 2022Review
- Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV.Cardiovascular drugs and therapy · 2022Review
- Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review.Journal of diabetes and metabolic disorders · 2021Review
- Viral Bad News Sent by EVAIL.Viruses · 2021Review
- Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review.BMC medicine · 2020Article
- The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews.Journal of lipid and atherosclerosis · 2020Article
- Statin therapy in COVID-19 infection.European heart journal. Cardiovascular pharmacotherapy · 2020Article
- Kidney Disease in HIV Infection.Journal of clinical medicine · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
HIV-infected individuals are at an increased risk of cardiovascular disease (CVD) and other HIV-related co-morbidities. This is due in part to dyslipidemia associated with antiretroviral therapy and increased inflammation and immune activation from chronic HIV infection. Statins not only have potent lipid-lowering properties but are also anti-inflammatory and immunomodulators. Studies suggest that statin therapy in the HIV-infected population may decrease the risk of CVD and other non-AIDS-defining co-morbidities. This review summarizes the recent literature on statin use in the HIV setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.